Cantor Fitzgerald last night upgraded Fulcrum Therapeutics (FULC) to Overweight from Neutral with a $10 price target Today’s share valuation is reflecting very little credit for pociredir, which is likely to have a role in a “very large” sickle cell disease market, the analyst tells investors in a research note. The firm says that with 100,000 U.S. patients, pociredir could be a drug to consider for many. Cantor says its physician feedback has been mixed, but still supports a role for pociredir.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FULC:
- Fulcrum Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
- Oppenheimer biotech analyst holds an analyst/industry conference call
- Cautious Outlook for Fulcrum Therapeutics Amid Phase 1b Progress and Enrollment Uncertainties
- Hold Rating for Fulcrum Therapeutics Amid Promising Trials and Competitive Challenges
- Fulcrum Therapeutics Reports Q1 2025 Progress and Stability
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue